Amarin (AMRN +18.0%)
is up on massive turnover of over 63M shares in apparent reaction to a
call between a patent lawyer and Jefferies’ Jared Holtz about the adverse patent ruling on Vascepa (icosapent ethyl) that caused the stock to plummet almost 71% yesterday.
The attorney said the company has an even-money chance to win on appeal citing a possible procedural error in the case.
https://seekingalpha.com/news/3557411-amarin-jumps-18-on-possible-patent-win
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.